Cyclacel Pharmaceuticals CYCC Stock News

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is running for the top in the premarket hours this morning, trading on gains of more than 38%. The gains come after the company announced that it has entered into a collaboration surrounding a potential treatment option for COVID-19. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

CYCC Announces COVID-19 Treatment Collaboration

In the release, Cyclacel Pharmaceuticals said that it has signed an agreement with the University of Edinburgh. Under the terms of the agreement, the parties will study CYC065 and CYC202 as potential early treatments for COVID-19 patients.

Both of these potential treatment options are clinical stage CDK2/9 inhibitors. It is believed that these treatments will reduce inflammatory responses in the lungs, ultimately reducing the chance of ARDS in COVID-19 patients.

CYCC said that the parties will access these medicines for suitability for use in safety and efficacy studies in COVID-19 patients. In the release, the company said that this work is part of a broader project known as STOPCOVID that is studying the inflammatory pathways that lead directly to COVID-19-related lung injury.

The STOPCOVID project has been awarded about $2.5 million in grants from LifeArk, and the University is seeking further funding for this work.

IN a statement, Professor Kev Dhaliwal, lead at STOPCOVID and Consultant in Respiratory Medicine at The University of Edinburgh, had the following to offer:

We are eager to evaluate the potential role of Cyclacel’s CDK inhibitors as enablers of inflammatory neutrophil apoptosis. Clinical data from international studies suggest that an early peripheral blood neutrophil response is associated with a poor outcome in COVID-19. If we can stop the inflammatory cascade early, we may be able to prevent or delay the severity of COVID-19 induced inflammation and the need for assisted ventilation in affected patients.

The above statement was followed up by Spiro Rombotis, President and CEO at CYCC. Here’s what he had to say:

We are excited to be contributing fadraciclib and seliciclib to the global effort to combat COVID-19. As previously reported, our two investigational CDK inhibitors suppress Mcl-1 in patients with proliferative diseases. Seliciclib has also been shown to efficiently suppress IL-6 transcription, a presumptive contributor to COVID-19 cytokine storm. Seliciclib is active in models of lung injury, pleurisy and rheumatoid arthritis and is undergoing clinical investigation in patients with rheumatoid arthritis. We are looking forward to working with The University of Edinburgh team and are humbled by the possibility of helping COVID-19 patients in need.

Why Investors Are Jumping With Excitement

There’s good reason for all of the excitement surrounding Cyclacel Pharmaceuticals this morning. First and foremost, COVID-19 is a pandemic, and stopping that pandemic will require both vaccines for those who have not become sick, and treatments for those who have.

While there are a few companies out there that are working on treatments, Cyclacel Pharmaceutcials is in line with the leaders. After all, most companies that have announced that they are working on a treatment have yet to announce anything tangible. At the same time, CYCC has two treatment options that show promise in the reduction of lung inflammation.

Considering the fact that the company is one of the frontrunners in the treatment of COVID-19, CYCC is a stock that investors should be paying close attention to.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.